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Abstract
Background: To contribute further to the classification of three CFTR amino acid changes
(p.I148T, p.R74W and p.D1270N) either as CF or CBAVD-causing mutations or as neutral
variations.
Methods: The CFTR genes from individuals who carried at least one of these changes were
extensively scanned by a well established DGGE assay followed by direct sequencing and familial
segregation analysis of mutations and polymorphisms.
Results: Four CF patients (out of 1238) originally identified as carrying the p.I148T mutation in
trans with a CF mutation had a second mutation (c.3199del6 or a novel mutation c.3395insA) on
the p.I148T allele. We demonstrate here that the deletion c.3199del6 can also be associated with
CF without p.I148T. Three CBAVD patients originally identified with the complex allele p.R74W-
p.D1270N were also carrying p.V201M on this allele, by contrast with non CF or asymptomatic
individuals including the mother of a CF child, who were carrying p.R74W-p.D1270N alone.
Conclusion: These findings question p.I148T or p.R74W-p.D1270N as causing by themselves CF
or CBAVD and emphazises the necessity to perform a complete scanning of CFTR genes and to
assign the parental alleles when novel missense mutations are identified.
Background
Cystic fibrosis (CF) is a common, often fatal disease with
a well-defined genetic cause, so that it is now recom-
mended in many countries in Europe and the United
States to offer genetic screening for CF mutations to iden-
tify carriers among adults with a positive family history of
CF, partners of individuals with CF, couples planning a
pregnancy, couples seeking prenatal care and, recently,
neonatal screening. Because of the mutational heteroge-
neity and the rarity of many mutations, most clinical DNA
laboratories offer tests that aim to detect 75–95 % of CF
alleles depending on the ethnic and geographic back-
grounds of the population, using available commercial
kits motsly including 20 to 31 mutations selected on the
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basis of their frequency as CF-causing mutations. A few
laboratories (most often national reference laboratories)
have developed the scanning of coding/flanking CFTR
sequences to detect unknown mutations. As of February
2004, about 1200 disease-causing mutations have been
identified in the cystic fibrosis transmembrane conduct-
ance regulator (CFTR) gene http://www.genet.sick
ids.on.ca/cgi-bin/webobjects/MUTATION Frameshift,
splice-site, nonsense, and in-frame but nonfunctional
deletions (such as p.F508del) are disease-causing muta-
tions. By contrast, the status of some missense mutations
is extremely difficult to assess and functional studies are
not available to diagnostic laboratories. Missense muta-
tions may represent, depending on the populations, up to
45% of mutations responsible for CF or CBAVD (congen-
ital bilateral absence of vas deferens). Moreover, due to
improved scanning strategies, a growing number of com-
plex alleles (several sequence changes on the same gene)
are thought to affect the expression of the disease pheno-
type by modulating the effect of a mutation [1-5]. The
most striking exemple is the length of the intron 8 poly-
thymidine tract (7, 9, or 5 thymidines) on exon 9 splicing
as a genetic modifier of the severity of the p.R117H muta-
tion [1]. Another exemple is the revertant mutation
p.R553Q which, when carried on the same gene as
p.F508del, is associated with a CF phenotype with normal
chloride concentration in sweat test [6] and which, when
expressed in heterologous cells, can partially correct the
processing and Cl- channel gating defects caused by the
p.F508del mutation [7].
With the start of population screening for CF carriers, new
data on the prevalence of some missense mutations have
been provided, questioning their involvement as disease-
causing mutations. In North American populations, mis-
sense mutations p.I148T and p.D1270N were found >100
times and >200 times, respectively, more frequently in
carrier screening than in CF patients [8,9]. Moreover, we
and others have found that individuals affected with CF or
CBAVD carry p.D1270N associated with p.R74W on the
same allele [p.R74W;p.D1270N] [10,11,5]. Similarly,
p.I148T has been shown to be associated with a CF phe-
notype only as a complex allele, i.e. when associated with
mutation c.3199del6 on the same gene [8]. A completely
asymptomatic male individual who is a compound heter-
ozygote for p.D1270N and p.I148T has been recently
identified [9]. These findings provided evidence that these
missense changes may not be the true mutations and
prompted us to reanalyze all the patients in our CF or
CBAVD cohort who had been originally diagnosed as
compound heterozygotes for either p.I148T or
[p.R74W;p.D1270N] and another mutation on the other
allele. The result of full scanning of CFTR sequences
showed that a second mutation (c.3199del6 or the novel
mutation c.3395insA) was associated in cis with p.I148T
in all individuals with a CF phenotype, and that a third
missense mutation (p.V201M) was associated in cis with
complex allele [p.D1270N;p.R74W] in patients with a
CBAVD phenotype in this series.
Methods
CFTR scanning for individuals with p.I148T or 
[p.D1270N;p.R74W]
From 1990 to 2003, we have analysed for CFTR mutations
genomic DNA from 437 families with CF and 170 with
isolated azoospermia caused by CBAVD, using a combi-
nation of mutation screening for known and scanning for
unknown mutations. The first step was the search of 31 CF
mutations detected by the ABI oligonucleotide ligation
assay and 3 common intronic mutations by using restric-
tion analysis. The second step was the scanning of coding/
flanking sequences by DGGE (Denaturing Gradient Gel
Electrophoresis) using 32 GC-clamped amplimers (which
in our experience detected 98% of CFTR mutants), fol-
lowed by sequencing to resolve abnormal PCR products
(BigDye terminator cycle sequencing on ABI 310 auto-
mate sequencer). Whenever possible, family members
were assayed for the mutations and associated polymor-
phisms. We detected 160 different mutations in the CF
group accounting for 97 % of CF alleles, and 64 different
mutations in the CBAVD group accounting for 85% of
CBAVD alleles, which represents one of the highest allelic
heterogeneity reported so far. Usually, mutation scanning
is stopped when two mutations are found to be in trans.
In this study, we analyzed by DGGE the entire coding and
flanking regions of the CFTR gene of individuals who had
been previously found to carry p.I148T or the complex
allele [p.R74W;p.D1270N] and assayed their relatives for
the additional sequence changes identified. We also re-
analyzed the CFTR gene of a CF patient who had been
originally described with c.394delTT in trans  of
c.3195del6 [12], now renamed c.3199del6 (see the
Results). Studies to determine the frequency of each
sequence alteration described in this report were per-
formed on 600 chromosomes from our general popula-
tion (Southern France). In addition, we also reanalyzed
two additional CF patients previously found to carry
p.I148T in the Lyon genetic center. The study was
approved by the institutional ethical committees and
informed consent was obtained from families.
Nomenclature
Gene variants and mutants are described using DNA and
protein designation: intronic changes, deletions, inser-
tions and frameshifts are reported at the cDNA level (c.)
and amino acid changes at the protein level (p.), as rec-
ommended in the Human Genome Variation Society web
page http://www.genomic.unimelb.edu.au/mdi/.BMC Medical Genetics 2004, 5:19 http://www.biomedcentral.com/1471-2350/5/19
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Results
A CF mutation (c.3199del6 or c.3395insA) is associated in 
cis with p.I148T in CF patients
Two out of 437 CF patients analyzed in Montpellier and
two out of 801 CF patients analyzed in Lyon were found
to carry p.I148T, which was initially thought to be one of
the two mutations responsible for CF in these patients.
However, thorough re-analysis of the entire CFTR
sequence determined that a CF mutation (c.3395insA or
c.3199del6) was present on the same gene in both cases
(table 1).
Mutation c.3199del6 can also occur alone as a CF-causing 
allele
Mutation c.3199del6 was found to be carried without
p.I148T in a young CF male with 394delTT on the other
allele, diagnosed at the age of 7 years on the basis of typi-
cal pulmonary disease, pancreatic insufficiency, poor
growth and positive sweat test [12]. Mutation c.3199del6
was initially described by us in 1994 in this patient as
c.3195del6 [12], in accordance with the first draft of
mutation nomenclature [13]. However, it occurred in the
same palindromic sequence in exon 17a than mutation
c.3199del6 reported in 1998 by Bozon et al. [14]. Both
mutations are expected to delete either amino acids
Val1022 and Ile1023, or Ile1023 and Val1024 from the
CFTR protein. As it is impossible to determine at the
genomic level in which part of the palindrome each of
them occurred, the most 3'copy of the repeat is arbitrarily
assigned to have been mutated, according to the current
rule [15]. Consequently, mutations c.3195del6 and
c.3199del6 should be considered as identical and
reported as c.3199_3204del. The familial segregation
analysis of polymorphisms covering the CFTR gene
showed that p.I148T, when present in individuals with a
CF phenotype, occurred on a unique haplotype carrying
IVS8-9T whatever the mutation in cis, c.3395insA or
c.3199del6 (table 1). By contrast, c.3199del6 without
p.I148T occurred on a different haplotype carrying IVS8-
7T.
Mutations p.I148T, c.3199del6 and c.3395insA were not
found on 600 chromosomes from our general
population.
Triple-mutant allele [p.R74W;p.V201M;p.D1270N] is 
found in males with CBAVD whereas double-mutant allele 
[p.R74W;p.D1270N] is found in asymptomatic individuals
Re-analysis of the CFTR gene in families carrying
[p.R74W;p.D1270N] identified a third mutation
(p.V201M) on the same chromosome in three unrelated
individuals with CBAVD (table 2). Only the double-
mutant p.R74W-p.D1270N was present in the two unaf-
fected individuals who were found with these changes in
our sample. The first case was a young boy who had been
initially suspected of having CF at age 4 years because of
allergic rhinitis but for whom the diagnosis of CF was later
ruled out; no other CFTR sequence alteration could be
identified and the sweat tests were negative (chloride val-
ues <40 mM). The second individual was the mother of a
CF girl who was compound heterozygous for p.F508del
and p.P67L. This woman, who was carrying p.P67L on
one CFTR gene and [p.R74W-p.D1270N] on the other
(table 1), was completely asymptomatic at age 45 years
Table 1: CFTR haplotypes associated with mutations found in CF patients carrying p.I148T in cis with c.3395insA or c.3199del6 and in 
one CF patient carrying c.3199del6 alone
Indiv No. Age at Diagnosis Phenotype CFTR Mutations CFTR haplotype
IVS1 IVS8 IVS8 IVS8 470 IVS17B IVS17B EGHa
CA CA TGm Tn TA CA
CF1 7 yrs CF-PI c.394delTT 21 23 10 9 M 36 13 B
c.3199del6 22 16 11 7 V 7 17 C
CF2 10 yrs CF-PS [c.3395insA;p.I148T] 21 23 10 9 M 7 17 B
p.R334W 22 17 11 7 V 46 13 A
CF3 6 ms CF-PI [c.3199del6;p.I148T] 21 23 10 9 M 7 17 B
p.F508del 21 23 10 9 M 31 13 B
CF4 3 yrs CF-PI [c.3199del6;p.I148T] 22 23 nd 9 M 7 17 B
p.F508del 22 17 nd 9 M 31 15 B
CF5 6 ms CF-PI [c.3199del6;p.I148T] 22 23 nd 9 M 7 17 B
p.F508del 22 23 nd 9 M 31 13 B
aEGH, extragenic haplotype XV2c/TaqI, KM19/PstI ; nd, not determined Patients CF1-3 were from the cohort of Montpellier (n = 437), patients 
CF4-5 were from the cohort of Lyon (n= 801).BMC Medical Genetics 2004, 5:19 http://www.biomedcentral.com/1471-2350/5/19
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and displayed three negative sweat tests (chloride values
<20 mM). The triple and double mutant alleles seem to
have occurred on the same haplotype TG11-T7-V470.
Discussion
p.I148T is a low penetrance CF mutation or a neutral 
polymorphism
Since its initial description in a CF Canadian patient with
pancreatic insufficiency [16], the mutation p.I148T,
which changes a conserved amino acid and occurs in the
first cytoplasmic loop of the CFTR protein, has been con-
sidered as a severe CF allele in many countries. It was
thought to be the second most common CF mutation in
the French Canadian population, accounting for 9.1% of
the French Canadian chromosomes [17], whereas in
France, p.I148T accounted for only 0.11 % of the CF alle-
les in a sample of 3,710 patients affected with the disease
[5]. p.I148T can now be detected by several commercially
available kits developed for routine screening of CF carri-
ers and for CF neonatal screening, and recently it has been
included in the core panel of 25 CF mutations recom-
mended by the American College of Medical Genetics
(ACMG) [18]. Thousands of individuals are being
screened for this mutation worldwide and it is possible
that several prenatal diagnosis have been or will be per-
formed. However there are now several lines of evidence
that question the role of p.I148T by itself in causing dis-
ease. First, compound heterozygosity for p.I148T and a
severe CF mutation was recently identified in several
healthy individuals [9,19]. When affected and unaffected
individuals carrying apparently the same mutational gen-
otype were re-analyzed for additional changes that could
explain the different phenotypes, p.I148T was found to be
associated in cis with another mutation, c.3199del6, in
patients with a classic CF phenotype, whereas healthy
adults who were compound heterozygous for p.I148T and
a severe CF mutation or homozygous for p.I148T did not
carry the deletion [8]. In a recent study, the p.I148T muta-
tion has been further documented to be linked with the
3199del6 mutation in all 24 CF patients of French Cana-
dian descent originally identified as compound hetero-
zygous for the p.I148T mutation and a second severe
CFTR mutation [20]. Second, p.I148T was found to be
over 100 times more common in two independent U.S.
carrier screening programmes than in CF patients: it
accounted for 6.4 to 7.7% of chromosomes detected in
the screened populations versus 0.06 to 0.068% of CF
chromosomes in CF patients [8. 9]. This discrepancy sug-
gests that p.I148T is either a poorly penetrant mutation or
a neutral polymorphism. Third, when transiently
expressed in epithelial cells, p.I148T mutant protein is
normally processed and is able to mediate normal chlo-
ride transport with properties identical with those of wild-
type cells [21]. As the mutant seems to suppress the ability
of CFTR to support HCO3- transport, it has been hypoth-
esized that p.I148T may contribute to disease through Cl-
coupled HCO3- altered transport; however, the major
CFTR functions are retained by the mutant [21]. Fourth,
we show in this study for the first time that p.I148T can be
associated with a frameshift mutation c.3395insA in exon
17b instead of in-frame deletion c.3199del6 in exon 17a.
Insertion c.3395insA (designated as c.3395_3396insA) is
a previously unreported mutation that is predictive of pre-
mature termination of translation at amino acid residue
1155. The truncated protein lacking the 325 last amino
acids is believed to be not functional and be degraded rap-
idly, generating no detectable protein. A CFTR alteration
producing a premature termination signal is a class I
mutation, considered severe enough to cause CF by itself
and exclude the contribution of any other sequence
Table 2: CFTR sequence changes found in individuals carrying missense alterations p.R74W, p.D1270N, or p.V201M
Mutations Haplotype
IVS1 IVS8 IVS8 IVS8 470 IVS17B IVS17B
CA CA TGm Tn TA CA
CBAVD1 p.R1066C 22 16 11 7 V 30 13
[p.R74W;p.V201M;p.D1270N] 22 16 11 7 V 31 13
CBAVD2 p.M952I 26 17 10 7 M 7 17
[p.R74W;p.V201M;p.D1270N] 22 16 11 7 V 31 13
CBAVD3 [p.R74W;p.V201M;p.D1270N] 22 16 11 7 V 31 13
[p.R74W;p.V201M;p.D1270N] 22 16 11 7 V 31 13
Individual non affected with CF
No mutation  21 nd 10 7 M 7 17
[p.R74W;p.D1270N] 22 nd 11 7 V 30 13
Asymptomatic mother of a CF affected girl
p.P67L 23 16 10 7 M 7 17
[p.R74;p.D1270N] 22 16 11 7 V 31 13BMC Medical Genetics 2004, 5:19 http://www.biomedcentral.com/1471-2350/5/19
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change on the same allele. Fifth, in contrast with other
studies that stated that only the complex allele
[p.I148T;9T;c.3199del6] appeared to be associated with a
classic CF phenotype [8], we demonstrate that c.3199del6
is associated with a CF phenotype even if the deletion
occurs on a chromosome that does not carry p.I148T,
which adds further value to the consideration that p.I148T
is not a true mutation but simply a polymorphism.
Although no functional test was performed to prove its
contribution to the severe phenotype, mutation
c.3199del6 has been considered as a defective allele as it
results in the loss of two amino acid residues in the TM10
domain of the CFTR protein and has not been detected in
non-CF alleles. Our data fully support the recent recom-
mendation that p.I148T should not be included in the
mutation panel selected for prenatal screening strategy
[22].
The complex allele [p.R74W;p.D1270N] may be not 
enough to cause disease
We and others had initially described p.R74W [23] and
p.D1270N [24] in isolation but they have since been
found in association in many CBAVD or CF patients
[10,11] and these two changes were thought to be delete-
rious, alone or in combination. A few complex alleles
have been expressed in heterologous systems to evaluate
the impact on CFTR processing and Cl- channel activity
and better understand the contribution of each missense
mutation on phenotype. When expressed in HeLa cells,
mutant p.R74W, p.D1270N and [p.R74W;p.D1270N] did
not affect CFTR processing, however a lower cAMP-
responsive anion conductance was observed with the dou-
ble mutant [p.R74W;p.D1270N] [3]. The assay suggested
that p.R74W alone should be considered as a polymor-
phism, p.D1270N alone could generate a CBAVD pheno-
type while the complex allele could produce a more severe
phenotype as p.R74W could enhance the effect of
p.D1270N [3]. However these findings have not yet been
confirmed by other studies.
We have found here that a triple-mutant
[p.R74W;p.V201M;p.D1270N] allele was carried in all
three patients with CBAVD whereas only the double
mutant [p.R74W;p.D1270N] allele was present in two
asymptomatic individuals including an obligate carrier
who was compound heterozygous for a CF mutation.
Another mother carrying [p.R74W;p.D1270N] in trans of
a CF mutation has been described previously; despite two
positive sweat tests she was absolutely asymptomatic [25].
Missense p.V201M in exon 6a changes a valine for a
methionine in the third transmembrane domain; it was
initially reported alone in a French patient with CBAVD
[26], then in Brazilian patients with CF [27].
Recent large scale screening for CF carrier showed that
p.D1270N was present 205 times more commonly in the
screened population than in the CF patients (frequency of
14% versus 0.068%); in addition, a completely asympto-
matic adult compound heterozygote for p.D1270N and
p.I148T has been identified [9]. Although it is not known
whether these alleles are associated or not with the third
change p.V201M, there are now enough evidence to ques-
tion the role of the complex allele [p.R74W;p.D1270N] as
being a CF or CBAVD mutation. Further experimental and
genetic investigations will be necessary to demonstrate the
role of p.V201M in causing disease.
Conclusions
This report further corroborates the recent hypothesis [9]
that p.I148T and p.R74W-p.D1270N may not be true CF/
CBAVD mutations. If these observations are further con-
firmed by a large multicentric study, they will have impor-
tant implications for genetic counseling of patients and
couples found to carry p.I148T or [p.R74W;p.D1270N].
They also pinpoint several important points in genetic
testing for CF : first, the necessity of scanning the whole
regions of the CFTR gene for diagnosis purposes, whatever
the cost; second the necessity to better standardize muta-
tion nomenclature, and third the usefulness of confirming
inheritance of mutations from both parents whenever
possible to avoid the risk for erroneously reporting
changes in trans that are in fact complex alleles.
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